Chronic Lymphocytic Leukemia

In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the rationale for evaluating a response-dependent treatment discontinuation strategy for older patients with previously untreated chronic lymphocytic leukemia. She highlighted the importance of determining an optimal discontinuation strategy in this patient population.

Jennifer A. Woymach, MD, provides background information on the AO41702 study, which evaluates targeted therapy ibrutinib or ibrutinib plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.<br /> &nbsp;

Lori Leslie, MD, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real-word clinics.

Chronic Lymphocytic Leukemia

In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the updated ELEVATE-TN data and ongoing research that is poised to define the optimal role of acalabrutinib in CLL at the 2019 ASH Annual Meeting.

Jeff P.&nbsp;<a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in&nbsp;<a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial&nbsp;&nbsp;evaluated acalabrutinib&nbsp;&nbsp;as a single agent or in combination with obinutuzumab versus obinutuzumab&nbsp;&nbsp;plus chlorambucil in patients with treatment-na&iuml;ve chronic lymphocytic leukemia.

Following the 2019 ASH Annual Meeting,&nbsp;Targeted Oncology&nbsp;spoke with experts from various specialties in hematology. The experts highlighted some of the top abstracts from the meeting that will impact the way multiple myeloma, leukemias, MPNs, and lymphomas are treated.